The genetic testing service 23andMe has certainly been under fire over the years, including a data breach in 2023. Now, with the announcement that the company has filed for bankruptcy in the U.S., ...
Hosted on MSN
I’d never use 23andMe or any other DNA testing service. Facebook has enough of my personal data already.
You’re worth a fortune. I was sorry to hear that 23andMe filed for Chapter 11 bankruptcy protection on Monday, but there would be a blizzard in Death Valley before I would ever use an online DNA kit ...
'I'm tired of being the product' You're worth a fortune. I was sorry that 23andMe filed for Chapter 11 bankruptcy protection last week, but there would be a blizzard in Death Valley before I would ...
A bankruptcy judge has approved the sale of the insolvent genetics firm 23andMe to a nonprofit run by one of the company's co-founders. The deal effectively avoids the controversial transfer of DNA ...
(Reuters) -Regeneron Pharmaceuticals said on Monday it will buy genomics firm 23andMe Holding for $256 million through a bankruptcy auction, and promised to prioritize the ethical use of DNA data from ...
With genetic testing company 23andMe filing for Chapter 11 bankruptcy protection and courting bidders, the DNA data of millions of users is up for sale. A Silicon Valley stalwart since 2006, 23andMe ...
Genetic testing company 23andMe never hit on a sustainable business model and went bankrupt. Now, it's being sold to a non-profit launched by the co-founder, delaying addressing data privacy concerns.
23andMe, a standard-bearer for the at-home health movement, announced on March 23 that it has filed for Chapter 11 bankruptcy to facilitate a sale, prompting many of ...
Following a data breach and bankruptcy, genetic testing service 23andMe will soon be in different hands. On Monday, biotechnology company Regeneron announced that it won the top bid in a bankruptcy ...
May 19 (Reuters) - Drugmaker Regeneron Pharmaceuticals (REGN.O), opens new tab is acquiring majority assets of bankrupt genetic testing firm 23andMe Holding for $256 million. The once-sizzling ...
(Reuters) - Regeneron Pharmaceuticals said on Monday it will buy genetic testing firm 23andMe Holding for $256 million through a bankruptcy auction, and promised to prioritize the ethical use of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results